Unternehmensübersicht
ZeroStack Corp. operates primarily through its subsidiary, Phatebo GmbH, which is engaged in the pharmaceutical distribution business within the German market. The company manages operations across two distinct segments: Commercial & Wholesale and Digital Assets, facilitating the distribution of various pharmaceutical goods and medical products for diverse health indications. This entity functions within the Financial Services sector, specifically under the Asset Management industry classification, where it manages capital and assets for stakeholders while navigating regulatory environments typical of the financial landscape. As of the latest available data, the company holds a market capitalization of $11.98M and generates annual revenue of $35.68M, supported by an employee base of 21 individuals. These valuation and revenue figures indicate that ZeroStack Corp. operates as a micro-cap entity with a relatively small market footprint, suggesting a niche operational scope rather than broad market dominance in the pharmaceutical distribution sector.
Finanzielle Gesundheit
The financial performance metrics for the trailing twelve months reveal a revenue of $35.68M contrasted against a net income of $-115,410,000 and an EBITDA of $-11,027,000. The substantial disparity between the positive revenue and the significant net loss highlights a highly aggressive or inefficient cost structure, where expenses substantially outpace gross earnings before interest and taxes. This negative EBITDA of $-11,027,000 further underscores the operational challenges the company faces in converting revenue into pre-tax profits. The company reports a free cash flow of $-5,176,000, which indicates a consumption of cash rather than generation, thereby limiting the company's current financial flexibility to fund organic growth or unexpected liabilities without external capital injection. Profitability is reflected in three key margin metrics: a Gross Margin of 4.6%, an Operating Margin of -54.8%, and a Profit Margin of 0.0%. The extremely low gross margin suggests high costs of goods sold relative to sales, while the deeply negative operating margin and zero profit margin confirm that the company is currently unprofitable on an operational and net basis. On the liability side, the company holds $5.60M in cash against $53.93M in total debt, resulting in a Debt to Equity ratio of 76.44, which characterizes the balance sheet as highly leveraged and potentially vulnerable to interest rate fluctuations or a downturn in business conditions. Liquidity is constrained by a Current Ratio of 1.01, indicating that current assets barely cover current liabilities, which presents a tight margin for error regarding short-term solvency. Finally, the Return on Equity stands at -307.5% and the Return on Assets at -9.3%, metrics that reveal a complete erosion of shareholder value and asset efficiency, signaling that management has not yet achieved the effectiveness required to generate positive returns on the capital invested.
Bewertungsanalyse
Valuation multiples for ZeroStack Corp. present a complex picture due to the absence of traditional earnings metrics, as the P/E Ratio (TTM) and Forward P/E are both N/A, implying that investors cannot value the stock based on historical or expected earnings per share. The Price to Book ratio is recorded at 0.07, which indicates that the market values the company at a fraction of its book value, suggesting a deep discount to the net asset value or a significant lack of confidence in the company's future earnings potential. Alternative valuation metrics provide additional context: the Price to Sales ratio is 0.34, while the EV/EBITDA stands at -5.47. These figures suggest that the company is trading at a very low multiple of its sales, but the negative EV/EBITDA confirms that the enterprise value is heavily influenced by the accumulated losses and debt obligations rather than operational profitability. The stock has experienced significant volatility over the past year, trading between a 52-Week High of $47.00 and a 52-Week Low of $4.78. Relative to this wide trading range, the current price sits well below the 52-week high, reflecting the severe performance issues and market sentiment downturn that have driven the price down from its yearly peak. The Beta value of 2.01 indicates that the stock's price volatility is more than double that of the broader market, meaning that the share price tends to move with much greater intensity than the overall market index, exposing investors to heightened risk during market corrections.
Growth & Income
The growth profile for the company shows a Revenue Growth (YoY) of 22.3%, whereas the Earnings Growth (YoY) is N/A due to the lack of positive net income. The fact that earnings growth is not available while revenue grows suggests that the company is expanding its top line but is simultaneously struggling with cost control or expansion-related expenses that prevent earnings from following a similar trajectory. As the company does not distribute dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, all available cash is effectively reinvested into the business operations or used to service debt rather than being returned to shareholders. This reinvestment strategy is typical for growth-stage companies, although in this instance, it occurs alongside significant cash burn and losses, raising questions about the sustainability of the revenue growth without a path to profitability. The overall growth and income profile for ZeroStack Corp. is characterized by strong top-line expansion in the pharmaceutical distribution sector but is currently devoid of income generation or dividend income, presenting a high-risk, high-volatility investment scenario driven by asset appreciation or loss rather than cash flow returns.